Abstract
Background: Cutaneous manifestations have been included in COVID-19 patients’ clinical spectrum. Our objective was to determine the association between skin lesions in children and SARS-CoV-2 infection, analyzing others possible infectious/autoimmune etiologies.
Material and methods: Observational, multicenter, cross-sectional study, about children with skin manifestations from April to May 2020. The diagnosis of SARS-CoV-2 was performed by PCR in nasopharyngeal exudate and/or presence of antibodies by serology.
Results: Sixty-two children were included, 9 (14.5%) presented positive antibodies to SARS-CoV-2, with no positive PCR to SARS-Cov-2 in those patients in whom it was made. Patients with positive serology to SARS-CoV-2 presented chilblains and/or vesicular-bullous skin lesions more frequently (66.7% vs. 24.5%, p=0.019). Generalized, urticarial and maculopapular rash was more common in patients with negative antibodies (37.7 vs. 0%, p=0.047), others pathogens were isolated in 41.5% of these patients. There were no significant differences in the positivity for autoantibodies between both groups.
Conclusion: In our study, the presence of chilblains-like and/or vesicular lesions were significantly related to SARS-CoV-2 previous contact.
Keywords: COVID-19; Chilblains; Exantema; Exanthema; Manifestaciones cutáneas; Perniosis; SARS-CoV-2; Skin manifestations.
【저자키워드】 COVID-19, SARS-CoV-2, chilblains, skin manifestations, Exanthema, Exantema, Manifestaciones cutáneas, Perniosis, 【초록키워드】 serology, antibody, cross-sectional, SARS-COV-2 infection, children, PCR, pathogen, nasopharyngeal, Patient, Manifestations, multicenter, skin, patients, Rash, Cutaneous, association, Contact, COVID-19 patient, manifestation, chilblain, autoantibody, lesion, skin lesion, no significant difference, both groups, material, positive, positive PCR, positive serology, etiologies, significantly, was performed, determine, presence of antibody, diagnosis of SARS-CoV-2, Generalized, 【제목키워드】 pandemic, children, First wave, skin lesion, the SARS-CoV-2,